首页> 美国卫生研究院文献>CPT: Pharmacometrics Systems Pharmacology >IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
【2h】

IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer

机译:IODNE:一种综合优化方法用于识别癌症精密医学已取消管制的子网

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Subnetwork analysis can explore complex patterns of entire molecular pathways for the purpose of drug target identification. In this article, the gene expression profiles of a cohort of patients with breast cancer are integrated with protein‐protein interaction (PPI) networks using, simultaneously, both edge scoring and node scoring. A novel optimization algorithm, integrated optimization method to identify deregulated subnetwork (IODNE), is developed to search for the optimal dysregulated subnetwork of the merged gene and protein network. IODNE is applied to select subnetworks for Luminal‐A breast cancer from The Cancer Genome Atlas (TCGA) data. A large fraction of cancer‐related genes and the well‐known clinical targets, ER1/PR and HER2, are found by IODNE. This validates the utility of IODNE. When applying IODNE to the triple‐negative breast cancer (TNBC) subtype data, we identified subnetworks that contain genes such as ERBB2, HRAS, PGR, CAD, POLE, and SLC2A1.
机译:子网分析可以探索整个分子途径的复杂模式,以实现药物靶标识别。在本文中,同时使用边缘评分和淋巴结评分,将一组乳腺癌患者的基因表达谱与蛋白质-蛋白质相互作用(PPI)网络整合在一起。提出了一种新的优化算法,即识别失调子网络的综合优化方法,以寻找基因和蛋白质网络融合后的最优失调子网络。 IODNE用于根据癌症基因组图谱(TCGA)数据选择Luminal-A乳腺癌的子网络。 IODNE发现了很大一部分与癌症相关的基因以及众所周知的临床靶标ER1 / PR和HER2。这验证了IODNE的实用性。将IODNE应用于三阴性乳腺癌(TNBC)亚型数据时,我们确定了包含ERBB2,HRAS,PGR,CAD,POLE和SLC2A1等基因的子网。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号